Back to results
US 8,944,804 B2Granted
Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
AssigneeLiquidia Technologies, Inc.
InventorsLloyd M. Robeson, Ginger Denison Rothrock
Life of this patent
Estimating the term…
Abstract
A medical device includes a textured surface having a predetermined nanostructure, wherein the nanostructure is less than about 500 nanometers in a broadest dimension. The textures nanostructure surface reduces friction between the medical device and biological tissue.
Claims18
A mold for fabricating nano-structured surfaces for medical articles, comprising:
- a mold having a first surface, wherein the first surface defines nano-structures less than about 500 nm in a broadest dimension configured for fabrication of medical articles for treating biologic tissues or conditions;
- and wherein the mold comprises a continuous layer of oligomer and wherein the oligomer is produced from polymerization of monomers selected from the group consisting of trifluorochloroethylene, trifluoroethylene, hexafluoro-iso-propyl (meth)acrylate, 1 H, 1H,3H- hexafluorobutyl(meth)acrylate, 1H, 1H,5H-octafluoropentyl (meth)acrylate, pentafluorophenyl (meth)acrylate, perfluoro(methyl vinyl ether), 1,1-dihydroperfluorobutyl (meth)acrylate, and combinations thereof;
- and a functional monomer included in the polymerization of the oligomer, wherein the functional monomer is selected from the group consisting of hydroxyethyl(meth)acrylate, (meth)acrylic acid, vinyl acetate, vinyl sulfonic acid, styrene sulfonic acid, 4-hydroxy styrene, 2-acrylamido-2-methyl propane sulfonate, maleic anhydride, glycidyl methacrylate, isocyanatoethyl methacrylate, and combinations thereof.
A system for fabricating nano-structured medical articles, the system comprising:
- a mold having a first surface, wherein the first surface defines nano-structures less than about 500 nm in a broadest dimension for molding nano-structures therefrom;
- wherein the mold comprises a continuous layer of oligomer and wherein the oligomer is produced from polymerization of monomers selected from the group consisting of trifluorochloroethylene, trifluoroethylene, hexafluoro-iso-propyl (meth)acrylate, 1 H, 1H,3H -hexafluorobutyl(meth)acrylate, 1H, 1H,5H -octafluoropentyl (meth)acrylate, pentafluorophenyl (meth)acrylate, perfluoro(methyl vinyl ether), 1,1-dihydroperfluorobutyl (meth)acrylate, and combinations thereof;
- and a biomaterial configured to be molded by the mold and form a medical article that treats a biologic tissue or condition;
- wherein the mold further comprises a functional monomer included in the polymerization of the oligomer, wherein the functional monomer is selected from the group consisting of hydroxyethyl(meth)acrylate, (meth)acrylic acid, vinyl acetate, vinyl sulfonic acid, styrene sulfonic acid, 4-hydroxy styrene, 2-acrylamido-2-methyl propane sulfonate, maleic anhydride, glycidyl methacrylate, isocyanatoethyl methacrylate, and combinations thereof.
1 more element
Dependencies are inferred from the claim text.